The improved survival rate for pediatric cancer patients is one of the greatest triumphs of recent medicine, but the late effects faced by these survivors have been uncovered through this new population of survivors. Many survivors of pediatric acute lymphoblastic leukemia (ALL) experience cognitive deficits in areas such as attention, memory, processing speed, and academic achievement following cancer treatment. Recent research has pointed to chemotherapeutic agents, host risk factors, and genetic predispositions as perpetrators of these deficits, although other factors are also under investigation. Consequently, the search for appropriate interventions for the amelioration of these deficits has dominated the literature in recent years. Due to the individualized and multi-faceted nature of the late effects, universally effective remediation methods are still nonexistent. However, pharmacological, non-pharmacological, and computerized cognitive intervention methods have all shown considerable promise for counteracting these cognitive deficits.